According to the latest report by IMARC Group, titled “Male Infertility Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028,” the global male infertility market size reached US$ 3.8 Billion in 2022. Male infertility refers to a medical condition wherein a man experiences difficulties in impregnating a fertile female partner, resulting in the inability or reduced likelihood of conceiving a child. It is caused due to various factors, including low sperm count, poor sperm motility, abnormal sperm morphology, hormonal imbalances, genetic disorders, testicular damage, and blockages in the reproductive system. Its treatment involves evaluating semen parameters, such as sperm count, motility, and morphology, assessing hormonal profiles, and conducting specialized tests, like genetic screening, hormone testing, and imaging studies. Besides this, it can also be treated using hormonal therapy, surgical procedures to correct blockages and abnormalities, and assisted reproductive technologies, such as in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI).
Global Male Infertility Market Trends:
The increasing prevalence of male infertility around the world due to changing lifestyles, stress, poor nutrition, exposure to environmental toxins, and aging represents one of the significant factors propelling the market growth. Additionally, the rising awareness among individuals about infertility issues and the increasing acceptance of treatments, prompted by reduced societal stigma, are driving the demand for male infertility solutions. The rising demand for personalized and precision medicine in infertility treatment is also contributing to market growth. Moreover, advancements in diagnostic procedures and the rising adoption of treatments like assisted reproductive technologies (ART) and in-vitro fertilization are further bolstering the growth of the market. The advent of cutting-edge technologies in sperm analysis and the development of novel drug therapies are offering promising market growth opportunities to industry investors. Furthermore, government initiatives promoting fertility treatment and increased investment in research and development (R&D) are impelling the market growth. The introduction of supportive policies, such as insurance coverage for infertility treatments and reimbursement options, is encouraging individuals and couples to seek medical assistance for male infertility. Looking forward, the market value is projected to reach US$ 5.2 Billion by 2028, expanding at a CAGR of 5.49% during 2023-2028.
- On the basis of the test type, the market has been segmented into sperm agglutination, DNA fragmentation technique, oxidative stress analysis, computer assisted semen analysis, sperm penetration assay, and others. DNA fragmentation technique currently accounts for the majority of the total market share.
- Based on the treatment, assisted reproductive technology and varicocele surgery represents the largest market segment, followed by medication.
- On the basis of the distribution channel, the market has been divided into hospitals pharmacies, pharmacies and drug stores, and online pharmacies. At present, hospitals pharmacies exhibit a clear dominance in the market.
- Based on the end user, the market has been segregated into hospitals and clinics, fertility centers, research institutes, and others. Fertility centers exhibit a clear dominance in the market.
- Region-wise, the market has been classified into North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. Amongst these, Europe enjoys the leading position in the market.
- The competitive landscape of the market has also been examined, with some of the key players being Andrology Solutions, CinnaGen Co., Halotech DNA, SCSA Diagnostics Inc., Vitrolife, Zydus Lifesciences Limited, Intas Pharmaceuticals Ltd. and Endo International plc.
|Base Year of the Analysis
||Test Type, Treatment, Distribution Channel, End User, Region
|| Asia Pacific, Europe, North America, Latin America, Middle East and Africa
||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
||Andrology Solutions, CinnaGen Co., Halotech DNA, SCSA Diagnostics Inc., Vitrolife, Zydus Lifesciences Limited, Intas Pharmaceuticals Ltd. and Endo International plc.
||10% Free Customization
|Report Price and Purchase Option
||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support
||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
134 N 4th St.
Brooklyn, NY 11249, USA
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800